Literature DB >> 9189058

Auranofin.

W F Kean1, L Hart, W W Buchanan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9189058     DOI： 10.1093/rheumatology/36.5.560

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN： 0263-7103


× No keyword cloud information.
  55 in total

1.  Inhibition of interleukin-12 production by auranofin, an anti-rheumatic gold compound, deviates CD4(+) T cells from the Th1 to the Th2 pathway.

Authors:  T S Kim; B Y Kang; M H Lee; Y K Choe; S Y Hwang
Journal:  Br J Pharmacol       Date:  2001-10       Impact factor: 8.739

2.  Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study.

Authors:  Francesca Magherini; Alessandra Modesti; Luca Bini; Michele Puglia; Ida Landini; Stefania Nobili; Enrico Mini; Maria Agostina Cinellu; Chiara Gabbiani; Luigi Messori
Journal:  J Biol Inorg Chem       Date:  2010-01-29       Impact factor: 3.358

3.  X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action.

Authors:  Derek Parsonage; Fang Sheng; Ken Hirata; Anjan Debnath; James H McKerrow; Sharon L Reed; Ruben Abagyan; Leslie B Poole; Larissa M Podust
Journal:  J Struct Biol       Date:  2016-02-12       Impact factor: 2.867

4.  Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis.

Authors:  Michael B Harbut; Catherine Vilchèze; Xiaozhou Luo; Mary E Hensler; Hui Guo; Baiyuan Yang; Arnab K Chatterjee; Victor Nizet; William R Jacobs; Peter G Schultz; Feng Wang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

5.  The antioxidant defense system Keap1-Nrf2 comprises a multiple sensing mechanism for responding to a wide range of chemical compounds.

Authors:  Makoto Kobayashi; Li Li; Noriko Iwamoto; Yaeko Nakajima-Takagi; Hiroshi Kaneko; Yuko Nakayama; Masami Eguchi; Yoshiko Wada; Yoshito Kumagai; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2008-11-10       Impact factor: 4.272

6.  Titanates deliver metal ions to human monocytes.

Authors:  John C Wataha; David T Hobbs; Jacqueline J Wong; Sami Dogan; Hai Zhang; K-H Chung; Mark C Elvington
Journal:  J Mater Sci Mater Med       Date:  2009-11-26       Impact factor: 3.896

Review 7.  The biological activity of auranofin: implications for novel treatment of diseases.

Authors:  J M Madeira; D L Gibson; W F Kean; A Klegeris
Journal:  Inflammopharmacology       Date:  2012-09-11       Impact factor: 4.473

8.  Auranofin is an effective agent against clinical isolates of Staphylococcus aureus.

Authors:  Nagendran Tharmalingam; Noelly Q Ribeiro; Danielle L da Silva; Mandar T Naik; Lana Ib Cruz; Wooseong Kim; Steven Shen; Jéssica D Dos Santos; Katarina Ezikovich; Erika Mc D'Agata; Eleftherios Mylonakis; Beth B Fuchs
Journal:  Future Med Chem       Date:  2019-07-12       Impact factor: 3.808

9.  Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative.

Authors:  Maria Pia Rigobello; Guido Scutari; Rita Boscolo; Alberto Bindoli
Journal:  Br J Pharmacol       Date:  2002-08       Impact factor: 8.739

Review 10.  Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?

Authors:  M Ostensen; R Ramsey-Goldman
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.